search
Back to results

Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Primary Purpose

Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Malignant Plasma Cell Neoplasms

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
cyclophosphamide
TBI
Sponsored by
H. Lee Moffitt Cancer Center and Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Myeloproliferative Disorders focused on measuring recurrent childhood acute lymphoblastic leukemia, refractory multiple myeloma, stage I multiple myeloma, stage II multiple myeloma, stage III multiple myeloma, stage I chronic lymphocytic leukemia, stage II chronic lymphocytic leukemia, stage III chronic lymphocytic leukemia, stage IV chronic lymphocytic leukemia, recurrent childhood acute myeloid leukemia, recurrent adult acute myeloid leukemia, recurrent adult acute lymphoblastic leukemia, refractory chronic lymphocytic leukemia, chronic phase chronic myelogenous leukemia, accelerated phase chronic myelogenous leukemia, blastic phase chronic myelogenous leukemia, adult acute myeloid leukemia in remission, adult acute lymphoblastic leukemia in remission, childhood acute myeloid leukemia in remission, childhood acute lymphoblastic leukemia in remission, polycythemia vera, primary myelofibrosis, essential thrombocythemia, refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia, de novo myelodysplastic syndromes, previously treated myelodysplastic syndromes, secondary myelodysplastic syndromes, refractory cytopenia with multilineage dysplasia, chronic eosinophilic leukemia, chronic neutrophilic leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, myelodysplastic/myeloproliferative neoplasm, unclassifiable, adult acute myeloid leukemia with t(8;21)(q22;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with t(15;17)(q22;q12), childhood myelodysplastic syndromes

Eligibility Criteria

15 Years - 50 Years (Child, Adult)All SexesDoes not accept healthy volunteers

DISEASE CHARACTERISTICS: Histologically confirmed diagnosis of one of the following: Acute lymphocytic leukemia (ALL): Complete remission (CR) 1 - high risk defined as overt CNS involvement or poor cytogenetics (additions, deletions, translocations, or multiple abnormalities) CR2 Induction failures Relapse - patients with at least 10% marrow blasts undergo at least one reinduction attempt Acute myelogenous leukemia (AML): CR1 - high risk defined as poor cytogenetics (deletions, additions, multiple abnormalities) CR2 Induction failures Relapse - patients with at least 10% marrow blasts undergo at least one reinduction attempt Chronic myelogenous leukemia (CML): Chronic phase (CP) 1 Accelerated phase/CP2 - patients in blast phase must undergo treatment and achieve a second chronic phase prior to transplant Chronic lymphocytic leukemia (CLL): Relapse - any stage; must have received no more than 3 prior regimens Multiple myeloma: At diagnosis - primary refractory Relapse (no more than 2) - sensitive disease Plasma cell leukemia Inability to achieve a complete remission after autologous transplant (no older than 40) Myelodysplasia - all subtypes Myeloproliferative disorders - patients with poor response to medical therapy or cytogenetic abnormalities Severe aplastic anemia (SAA): Very SAA - at diagnosis SAA - induction therapy Donors must be a phenotypic (6 out of 6) match or a one antigen (A or B) mismatch PATIENT CHARACTERISTICS: Age: 15 to 50 Performance status: Karnofsky 80-100% Life expectancy: Not specified Hematopoietic: See Disease Characteristics Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT and SGPT no greater than 3 times normal PT/PTT normal Renal: Creatinine no greater than 2.0 mg/dL Creatinine clearance at least 60 mL/min Cardiovascular: Left ventricular ejection fraction at least 45% No myocardial infarction within past 6 months No uncontrolled arrhythmias Pulmonary: FEV1 at least 50% DLCO at least 50% predicted Other: No active serious infection HIV negative Not pregnant or nursing No uncontrolled diabetes mellitus or thyroid disease PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See Disease Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified

Sites / Locations

  • Moffitt Cancer Center

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Cy/TBI

Arm Description

cyclophosphamide and total body irradiation (TBI)

Outcomes

Primary Outcome Measures

event free survival (EFS)
EFS determined by the Kaplan-Meier product limit method

Secondary Outcome Measures

Incidence of graft versus host disease
incidence and severity of acute and chronic GVHD

Full Information

First Posted
May 2, 2000
Last Updated
October 24, 2012
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00005622
Brief Title
Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
Official Title
Allogeneic Bone Marrow Transplantation Using Closely Matched Related and Unrelated Donors
Study Type
Interventional

2. Study Status

Record Verification Date
October 2012
Overall Recruitment Status
Completed
Study Start Date
May 1996 (undefined)
Primary Completion Date
September 2005 (Actual)
Study Completion Date
July 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
National Cancer Institute (NCI)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
RATIONALE: Giving chemotherapy and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related or unrelated donor, that closely matches the patient's blood, are infused into the patient they may help the patient's bone marrow to make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying how well donor bone marrow transplant works in treating patients with leukemia, lymphoma, or nonmalignant hematologic disorders.
Detailed Description
OBJECTIVES: Determine the survival of allogeneic bone marrow transplantation using closely matched related and unrelated donors in patients with malignant or nonmalignant hematological disorders. Determine the incidence and severity of acute and chronic graft versus host disease with this treatment regimen in these patients. Determine the relapse rates with this treatment regimen in those patients with malignant disorders. Determine the incidence and severity of infectious complications associated with this treatment regimen in these patients. OUTLINE: Patients receive cyclophosphamide IV over 1 hour on days -6 and -5, total body radiotherapy on days -3 through 0, and allogeneic bone marrow transplantation on day 0. Patients with acute lymphocytic leukemia (ALL) receive intrathecal methotrexate at the beginning of the study. If CNS involvement is documented, patients receive a second dose of methotrexate 48 hours later followed by oral leucovorin calcium every 6 hours for 4 doses. Patients with ALL and/or CNS involvement receive intrathecal methotrexate every other week for 12 weeks after transplant. Patients with prior CNS involvement receive radiotherapy for 2.5 weeks prior to transplant. Patients with ALL receive total body radiotherapy for 5 consecutive days prior to transplant. Patients are followed once a week for 3 months, and then monthly for 1 year. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study over 6 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Keywords
recurrent childhood acute lymphoblastic leukemia, refractory multiple myeloma, stage I multiple myeloma, stage II multiple myeloma, stage III multiple myeloma, stage I chronic lymphocytic leukemia, stage II chronic lymphocytic leukemia, stage III chronic lymphocytic leukemia, stage IV chronic lymphocytic leukemia, recurrent childhood acute myeloid leukemia, recurrent adult acute myeloid leukemia, recurrent adult acute lymphoblastic leukemia, refractory chronic lymphocytic leukemia, chronic phase chronic myelogenous leukemia, accelerated phase chronic myelogenous leukemia, blastic phase chronic myelogenous leukemia, adult acute myeloid leukemia in remission, adult acute lymphoblastic leukemia in remission, childhood acute myeloid leukemia in remission, childhood acute lymphoblastic leukemia in remission, polycythemia vera, primary myelofibrosis, essential thrombocythemia, refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia, de novo myelodysplastic syndromes, previously treated myelodysplastic syndromes, secondary myelodysplastic syndromes, refractory cytopenia with multilineage dysplasia, chronic eosinophilic leukemia, chronic neutrophilic leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, myelodysplastic/myeloproliferative neoplasm, unclassifiable, adult acute myeloid leukemia with t(8;21)(q22;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with t(15;17)(q22;q12), childhood myelodysplastic syndromes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
72 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cy/TBI
Arm Type
Other
Arm Description
cyclophosphamide and total body irradiation (TBI)
Intervention Type
Drug
Intervention Name(s)
cyclophosphamide
Intervention Description
Cyclophosphamide is administered at a dose of 60 mg/kg on each of two successive days (Days -6 and -5)
Intervention Type
Radiation
Intervention Name(s)
TBI
Intervention Description
FTBI is performed on day -3 through day 0 The total dose of radiation is 1,320 cGy.
Primary Outcome Measure Information:
Title
event free survival (EFS)
Description
EFS determined by the Kaplan-Meier product limit method
Time Frame
five year post transplant
Secondary Outcome Measure Information:
Title
Incidence of graft versus host disease
Description
incidence and severity of acute and chronic GVHD
Time Frame
five years post transplant

10. Eligibility

Sex
All
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed diagnosis of one of the following: Acute lymphocytic leukemia (ALL): Complete remission (CR) 1 - high risk defined as overt CNS involvement or poor cytogenetics (additions, deletions, translocations, or multiple abnormalities) CR2 Induction failures Relapse - patients with at least 10% marrow blasts undergo at least one reinduction attempt Acute myelogenous leukemia (AML): CR1 - high risk defined as poor cytogenetics (deletions, additions, multiple abnormalities) CR2 Induction failures Relapse - patients with at least 10% marrow blasts undergo at least one reinduction attempt Chronic myelogenous leukemia (CML): Chronic phase (CP) 1 Accelerated phase/CP2 - patients in blast phase must undergo treatment and achieve a second chronic phase prior to transplant Chronic lymphocytic leukemia (CLL): Relapse - any stage; must have received no more than 3 prior regimens Multiple myeloma: At diagnosis - primary refractory Relapse (no more than 2) - sensitive disease Plasma cell leukemia Inability to achieve a complete remission after autologous transplant (no older than 40) Myelodysplasia - all subtypes Myeloproliferative disorders - patients with poor response to medical therapy or cytogenetic abnormalities Severe aplastic anemia (SAA): Very SAA - at diagnosis SAA - induction therapy Donors must be a phenotypic (6 out of 6) match or a one antigen (A or B) mismatch PATIENT CHARACTERISTICS: Age: 15 to 50 Performance status: Karnofsky 80-100% Life expectancy: Not specified Hematopoietic: See Disease Characteristics Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT and SGPT no greater than 3 times normal PT/PTT normal Renal: Creatinine no greater than 2.0 mg/dL Creatinine clearance at least 60 mL/min Cardiovascular: Left ventricular ejection fraction at least 45% No myocardial infarction within past 6 months No uncontrolled arrhythmias Pulmonary: FEV1 at least 50% DLCO at least 50% predicted Other: No active serious infection HIV negative Not pregnant or nursing No uncontrolled diabetes mellitus or thyroid disease PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See Disease Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Teresa Field, MD, PhD
Organizational Affiliation
H. Lee Moffitt Cancer Center and Research Institute
Official's Role
Study Chair
Facility Information:
Facility Name
Moffitt Cancer Center
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612-9497
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

We'll reach out to this number within 24 hrs